Johnson & Johnson cut PSA by at least 50% in 73% of heavily treated patients. Can two bispecifics crack prostate cancer?
Johnson & Johnson’s pasritamig plus JNJ-9401 regimen produced a 73% PSA50 rate in 15 heavily treated prostate cancer patients.
Pharma & Biotech